A 38-year-old woman with systemic lupus erythematosus (SLE) manifested by tiredness, polyarthritis, lymphopaenia, elevated antidouble-stranded DNA antibodies, and hypocomplementaemia was initiated on azathioprine and hydroxychloroquine. After 2 weeks of treatment, she developed extensive erythematous raised skin patches, facial oedema, and desquamation of nasal and oral mucosa. Both drugs were discontinued and she improved within 4-7 days. Since hydroxychloroquine is associated with more hypersensitivity reactions than azathioprine, the latter was reintroduced, but 2 days later, the patient developed severe recurrent skin lesions ( figure 1A-C) . Skin biopsy showed band-like lymphocytic infiltrate with focal vacuolar interface 
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DESCRIPTION
A 38-year-old woman with systemic lupus erythematosus (SLE) manifested by tiredness, polyarthritis, lymphopaenia, elevated antidouble-stranded DNA antibodies, and hypocomplementaemia was initiated on azathioprine and hydroxychloroquine. After 2 weeks of treatment, she developed extensive erythematous raised skin patches, facial oedema, and desquamation of nasal and oral mucosa. Both drugs were discontinued and she improved within 4-7 days. Since hydroxychloroquine is associated with more hypersensitivity reactions than azathioprine, the latter was reintroduced, but 2 days later, the patient developed severe recurrent skin lesions (figure 1A-C). Skin biopsy showed band-like lymphocytic infiltrate with focal vacuolar interface changes consistent with early Stevens-Johnson syndrome (figure 2). She had no symptoms or signs of respiratory, urinary or soft tissue infection. Urine and blood cultures were negative. Chest X-rays were normal. She did not required antibiotics during the hospitalisation. She was treated with high-dose intravenous immunoglobulins (IVIGs) over a 5-day period (30 g/day). After 2 days of initiating therapy, she improved as evidenced by resolution of facial oedema, and decreased erythema and desquamation ( figure 3A-C) . Hydroxychloroquine was restarted 5 months later without adverse events. The patient did not present recurrent lesions after 6-month follow-up.
Our patient developed Stevens-Johnson syndrome most likely secondary to use of azathioprine. She had a remarkable clinical response to IVIG. Patients with SLE have an increased risk for Stevens-Johnson syndrome either because of the SLE itself or due to the use of immunosuppressive drugs such as azathioprine. 1 Since cutaneous adverse events to azathioprine are rare, they are usually recognised on resumption of therapy. 2 These reactions are dose dependent and occur within the first 4 weeks of exposure. There is no consensus on whether IVIG is better than conservative therapy for Stevens-Johnson syndrome, but some reports have shown its efficacy. 3 In summary, we present an additional case in which high-dose IVIG was successful in accelerating the recovery period and stopping further disease progression of Stevens-Johnson syndrome. 
